

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM769456

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
RxAnte, Inc.		11/21/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Trinity Capital Inc.		
Street Address:	1 N 1st Street, Floor 3		
City:	Phoenix		
State/Country:	ARIZONA		
Postal Code:	85004		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 10			
Property Type	Number	Word Mark	
Registration Number:	4650355	RXANTE	
Registration Number:	4650356	KNOW THE FUTURE. THEN CHANGE IT.	
Registration Number:	4650357	THE FUTURE OF PATIENT ADHERENCE	
Registration Number:	4679809	VFA	
Registration Number:	4783628	RXEFFECT	
Registration Number:	4945951	PREDICT.DECIDE.LEARN.	
Serial Number:	88737414	MOSAIC	
Serial Number:	88737518	MOSAIC PHARMACY SERVICE	
Serial Number:	97340193		
Serial Number:	97340139	MOSAIC PHARMACY SERVICE BY RXANTE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8004945225		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	JAY DASILVA		
Address Line 1:	1025 CONNECTICUT AVE., NW, STE. 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	WASHINGTON, D.C. 20036		

OP \$265.00 4650355

ATTORNEY DOCKET NUMBER:	1838176 TM
NAME OF SUBMITTER:	Yvette Stohler
SIGNATURE:	/Yvette Stohler/
DATE SIGNED:	11/22/2022

Total Attachments: 6

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page1.tif

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page2.tif

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page3.tif

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page4.tif

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page5.tif

source=Trinity- RxAnte IP Security_Agreement 11-21-22#page6.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") dated as of November 21, 2022, is made by RXANTE, INC., a Delaware corporation (the "Grantor"), in favor of TRINITY CAPITAL INC., a Maryland corporation ("Lender").

RECITALS

A. Grantor has entered into a Loan and Security Agreement with Lender, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Lender for its benefit a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. **Grant of Security Interest.** To secure its obligations under the Loan Agreement, Grantor grants and pledges to Lender for its benefit a security interest in all of Grantor's right, title and interest in, to and under its intellectual property to the extent constituting Collateral (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those registered copyrights and copyright applications set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the registered patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those registered trademarks and trademark applications set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

- (h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;
- (i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and
- (j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Lender.

Grantor hereby authorizes Lender to (a) modify this Agreement by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains and notifies Lender of subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Lender with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Lender's express prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Lender's successors and assigns.

6. Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[Balance of Page Intentionally Left Blank.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed as of the day and year first above written.

GRANTOR:

RXANTE, INC.,
a Delaware corporation

DocuSigned by:

By: Joshua Benner
Name: Joshua Benner
Title: Chief Executive Officer

LENDER:

TRINITY CAPITAL INC.,
a Maryland corporation

DocuSigned by:

By: Sarah Stanton
Name: Sarah Stanton
Title: General Counsel and Chief Compliance
Officer

COPY VIEW

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

COPYRIGHTS

None.

COPY VIEW

EXHIBIT B**PATENTS**


ISSUED US PATENTS		
Name	Date of Patent Grant Date	Patent Number
Medical Accountable Provider Platform	October 23, 2018	US 10,108,975 B1
Value of Future Adherence	June 11, 2019	US 10,318,897 B1
Value of Future Adherence (Continuation Patent)	July 7, 2020	US 10,706,372 B1
Healthcare Management System and Method	February 8, 2022	US 11,241,029 B1
Medical Accountable Provider Platform (Continuation Patent)	May 17, 2022	US 11,334,902 B1

US PATENT APPLICATIONS FILED¹		
Name	Date of Application	Application Number
Systems and Method for Risk Based Medication Management Program	April 30, 2015	14/701,073
Systems and Methods for Processing and Communicating Intervention Data	March 22, 2018	15/928,763
Value of Future Adherence (Continuation Patent)	July 1, 2020	16/918,517
Systems and Method for Managing Medications	January 6, 2021	17/142,480
Systems and Method for Therapeutic Decision Support	October 8, 2021	17/497,327
Healthcare Management System and Method	December 27, 2021	17/562,110
Systems and Methods for Generating User Interface Data Associated with Adherence Intervention Data	January 13, 2022	17/575,111
Medical Accountable Provider Platform (Continuation)	May 13, 2022	17/444/269

¹ NTD: The patent applications were filed on a nonpublication basis, please redact before filing this IPISA.
DMS 23947678.3

EXHIBIT C**TRADEMARKS**

REGISTERED US TRADEMARKS/SERVICE MARKS		
Mark and Type	Registration Date	Registration Number
RxAnte (standard character mark) – Service Mark	December 2, 2014	4650355
Know the Future, Then Change It (standard character mark) – Service Mark	December 2, 2014	4650356
The Future Of Patient Adherence (standard character mark) – Service Mark	December 2, 2014	4650357
VFA (standard character mark) -Service Mark	January 27, 2015	4679809
RxEffekt (standard character mark) – Service Mark	July 28, 2015	4783626
Predict Decide Learn (standard character mark) – Service Mark	April 26, 2016	4945951

US TRADEMARKS/SERVICE MARKS APPLICATIONS FILED		
Mark and Type	Application Date	Application Number
Mosaic (standard character mark) – Service Mark	December 23, 2019	88/737,414
Mosaic Pharmacy Service (standard character mark) – Service Mark	December 23, 2019	88/737,518
Mosaic Pill Design – Design Mark 	March 31, 2022	97/340,193
Mosaic Pharmacy Service by RxAnte (standard character mark) – Service Mark	March 31, 2022	97/340,139